European regulators are to hasten development of Janssen’s CAR-T therapy for patients with multiple myeloma, after promising early-stage trial results.
This year’s eyeforpharma Barcelona conference might have seemed all doom and gloom at the outset, with many predicting the downfall of pharma as we know it – but there were plenty of speake
Janssen has struck a deal with Arrowhead Pharmaceuticals to develop an RNA interference drug to treat hepatitis B viral infection, worth up to $3.7 billion.